Comparison of SGLT2 inhibitors with DPP-4 inhibitors combined with metformin in patients with acute myocardial infarction and diabetes mellitus

Table 4 1-year exploratory outcomes in propensity score matched patients

	Before IPTW			After IPTW
Characteristics	SGLT2i group	DPP-4i group	p-value	SGLT2i group	DPP-4i group	p-value
Characteristics	(n = 186)	(n = 593)	p-value	(n = 537)	(n = 532)	p-value
1-year follow-up
HbA1c, %	7.03 ± 1.39	7.08 ± 1.45	0.804	7.06 ± 1.18	6.95 ± 1.36	0.483
LVEF, %	53.97 ± 10.71	55.41 ± 10.12	0.284	56.41 ± 11.06	55.08 ± 10.29	0.448
LVEF < 40%	7 (9.2)	14 (5.4)	0.232	15 (8.0)	16 (5.9)	0.559
Change from baseline during 1-year follow-up
Δ HbA1c	-1.15 ± 2.00	-0.65 ± 1.90	0.041	-0.76 ± 1.73	-0.80 ± 2.00	0.910
Δ LVEF	6.10 ± 8.30	2.95 ± 10.34	0.007	6.91 ± 8.91	3.13 ± 10.41	0.027

Values are presented as number (percentage) for categorical values and means ± standard deviation for continuous variables
DPP-4i = dipeptidyl peptidase-4 inhibitors; HbA1c = hemoglobin A1c; IPTW = inverse probability of treatment weighting; LVEF = left ventricular ejection fraction; SGLT2i = sodium-glucose cotransporter 2 inhibitors

ISSN: 1475-2840